Surrozen, Inc. Common - SRZN STOCK NEWS

Surrozen, a clinical-stage biotechnology company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. Pacific time. The presentation will focus on their innovative therapies targeting the Wnt pathway for tissue repair and regeneration. A live audio webcast will be available on Surrozen's Investor Relations website. Surrozen aims to address diseases like inflammatory bowel disease and certain neurological disorders through its targeted therapies.

Surrozen, Inc. (Nasdaq: SRZN) reported Q3 2022 financial results, with cash reserves at $78.4 million, down from $92.7 million in Q2 2022. The net loss narrowed to $13.4 million from $14.0 million a year prior. Enrollment in the SZN-1326 Phase 1 trial was paused due to adverse liver events, while SZN-043 is ongoing with mild liver transaminase elevations observed. Surrozen partnered with Boehringer Ingelheim for SZN-413, receiving a $12.5 million upfront payment and potential future milestones of $586.5 million. Research expenses decreased to $8.6 million, while general administrative expenses rose to $5.0 million.

Surrozen, Inc. (Nasdaq: SRZN) presented preclinical data at the United European Gastroenterology Week that supports its drug candidates SZN-1326 and SZN-043 for treating ulcerative colitis and severe liver diseases, respectively. SZN-043 showed rapid hepatocyte proliferation and safety in non-clinical studies, while SZN-1326 improved epithelial healing and reduced collagen deposition. Both candidates exhibited no adverse effects in toxicology studies. The Phase 1 clinical trials for both candidates are ongoing, initiated in May and June 2022.

Surrozen has announced a significant collaboration with Boehringer Ingelheim to develop SZN-413, a bi-specific antibody aimed at treating retinal diseases. This agreement marks Surrozen's first strategic partnership and includes an upfront payment of $12.5 million, plus potential milestone payments of up to $586.5 million. SZN-413 utilizes Surrozen's SWAP™ technology to target Fzd4-mediated Wnt signaling, promoting retinal vessel regrowth and reducing vascular leakage. Boehringer will take on research and commercialization responsibilities following an initial joint research period.

Surrozen (Nasdaq: SRZN) announced promising results from recent studies published in Translational Vision Science and Technology. The research highlighted SZN-413, a bi-specific antibody targeting FZD4 and LRP5, as a potential novel treatment for diabetic retinopathy, a major cause of vision loss. SZN-413 was shown to effectively reduce retinal vascular leakage by approximately 80% and significantly diminished areas of pathologic neovascularization. This mechanism may address both retinal non-perfusion and leakage, indicating a potential breakthrough for retinal vascular diseases.

Surrozen, Inc. (SRZN) reported Q2 2022 financial results and provided a corporate update, marking its transition to a clinical stage company. The company has initiated Phase 1 trials for lead candidates SZN-1326, targeting moderate to severe ulcerative colitis, and SZN-043, aimed at severe alcoholic hepatitis. Both candidates have shown promising preclinical results without adverse effects. Additionally, preclinical data on SZN-413 for diabetic retinopathy was presented. The company emphasized ongoing advancements in its Wnt modulation therapies for tissue repair.

Surrozen, Inc. (Nasdaq: SRZN) has initiated a two-part Phase 1 clinical trial for SZN-043, a novel bispecific protein targeting ASGR1, aimed at treating severe alcoholic hepatitis. The trial's first part involves administering single doses to healthy volunteers, with doses ranging from 3 mg to 30 mg. The second part will assess multiple doses in patients with liver cirrhosis. The primary endpoint focuses on safety and tolerability. Preclinical studies indicate SZN-043 may enhance liver function and reduce fibrosis without adverse effects.

Surrozen, Inc. (NASDAQ: SRZN) announced significant advancements in its lead therapeutic programs at Digestive Disease Week 2022. The company's clinical study of SZN-1326 is currently underway, targeting moderate to severe ulcerative colitis, while the SZN-043 study is expected to commence in Q3 2022 for severe alcoholic hepatitis. Presentations highlighted SZN-1326's mechanism in promoting colonic mucosal healing and SZN-043's role in enhancing hepatocyte proliferation. Both candidates showed promising results in preclinical models, demonstrating therapeutic potential without adverse effects.

Surrozen (Nasdaq: SRZN) announced the dosing of the first subject in its three-part Phase 1 clinical trial for SZN-1326, aimed at treating moderate to severe ulcerative colitis. This milestone was achieved a quarter earlier than expected. The trial includes safety and pharmacokinetics evaluations with doses ranging from 25 mg to 1500 mg. SZN-1326, a bi-specific antibody targeting the Wnt pathway, demonstrated strong preclinical results, suggesting potential for tissue repair and anti-inflammatory effects without adverse effects observed in animal studies.